STING modulation for the treatment of triple negative breast cancer using novel glyco-based delivery systems Part 1: design and synthesis of novel glyco-based delivery systems

Breast cancer affect one out of eight women worldwide. Triple-negative breast cancer is an invasive breast cancer that is estrogen receptor-negative, progesterone receptor-negative, and HER2-negative. Triple-negative breast cancer is a type of breast cancer that is usually more aggressive, harder to treat, and more likely to come back (recur) than cancers that are hormone receptor-positive or HER2-positive. About 10-15% of all breast cancers are triple-negative. There is no successful treatment for triple negative breast cancer. Exploring novel avenues to target these particular cancer cells would be of great benefit to cure this unmet medical need. In addition, these cancers are highly metastatic. This proposal aims at using novel nanomaterials for the highly selective targeting of anti-cancer agents, thus limiting their cytotoxicity and side-effects. The proposed nanomedicine is composed of liposomal formulations that have been very successful in the recent pandemic COVID-19 (Pfizer and Moderna vaccines

Faculty Supervisor:

Rene Roy

Student:

Partner:

Bowhead Health

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

Université du Québec à Montréal

Program: